Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells

Neuroscience

Volumn 314, Issue , 2016, Pages 47-63

  Kata, D ^a   Foldesi I ^a   Feher, L Z ^b   Hackler, L ^b   Puskas, L G ^b   Gulya, K ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b AVIDIN LTD   (Hungary)

Author keywords

Anti inflammation; Gene expression; Lipopolysaccharide; Phagocytosis; Pro inflammation; Rosuvastatin

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; CXCL1 GENE; CXCL5 GENE; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE; GENE EXPRESSION; HSPB1 GENE; MBL2 GENE; MICROGLIA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; UPREGULATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; FOREBRAIN; GENETICS; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MICROGLIA; PHAGOCYTOSIS; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; ROSUVASTATIN CALCIUM;

EID: 84949567296     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.11.053     Document Type: Article

References (91)

1. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37:13-25.
2. Ahmed Z., Shaw G., Sharma V.P., Yang C., McGowan E., Dickson D.W. Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 2007, 55:687-700.
3. Asztalos B.F., Le Maulf F., Dallal G.E., Stein E., Jones P.H., Horvath K.V., McTaggart F., Schaefer E.J. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins. Am J Cardiol 2007, 99:681-685.
4. Atienza J.M., Zhu J., Wang X., Xu X., Abassi Y. Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 2005, 10:795.
5. Banati R.B., Gehrmann J., Schubert P., Kreutzberg G.W. Cytotoxicity of microglia. Glia 1993, 7:111-118.
6. Bodovitz S., Klein W.L. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996, 271:4436-4440.
7. Boisvert W.A., Rose D.M., Johnson K.A., Fuentes M.E., Lira S.A., Curtiss L.K., Terkeltaub R.A. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol 2006, 168:1385-1395.
8. Burg J.S., Espenshade P.J. Regulation of HMG-CoA reductase in mammals and yeast. Progr Lipid Res 2011, 50:403-410.
9. Concannon C.G., Gorman A.M., Samali A. On the role of Hsp27 in regulating apoptosis. Apoptosis 2003, 8:61-70.
10. Cordle A., Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J Neurosci 2005, 25:299-307.
11. Davidson M.H. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Exp Opin Invest Drugs 2002, 11:125-141.
12. El Khoury J., Luster A.D. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 2008, 29:626-632.
13. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007, 13:432-438.
14. Ellis L.C., Hawksworth G.M., Weaver R.J. ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol Appl Pharmacol 2013, 269:187-194.
15. Eltayeb S., Berg A.L., Lassmann H., Wallström E., Nilsson M., Olsson T., Ericsson-Dahlstrand A., Sunnemark D. Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanism of MOG-induced EAE. J Neuroinflamm 2007, 4:14.
16. Fabian G., Farago N., Feher L.Z., Nagy L.I., Kulin S., Kitajka K., Bito T., Tubak V., Katona R.L., Tiszlavicz L., Puskas L.G. High-density real-time PCR-based in vivo toxicogenomic screen to predict organ-specific toxicity. Int J Mol Sci 2011, 12:6116-6134.
17. Famer D., Wahlund L.O., Crisby M. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD. Biochem Biophys Res Commun 2010, 402:367-372.
18. Floden A.M., Combs C.K. Beta-amyloid stimulates murine postnatal and adult microglia cultures in a unique manner. J Neurosci 2006, 26:4644-4648.
19. Fujita H., Tanaka J., Toin R., Tateishi N., SuzugI Y., Matsuda S., Sakanaka M., Maedap N. Effects of GM-CSF and ordinary supplements on the ramification of microglia in culture: a morphometrical study. Glia 1996, 18:269-281.
20. Gamba P., Testa G., Gargiulo S., Staurenghi E., Poli G., Leonarduzzi G. Oxidized cholesterol as the driving force behind the development of Alzheimer's disease. Front Aging Neurosci 2015, 7:119.
21. Gao Y., Lu X.C., Yang H.Y., Liu X.F., Cao J., Fan L. The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses. Int J Mol Med 2012, 30:765-774.
22. Gay F. Activated microglia in primary MS lesions: defenders or aggressors?. Int MS J MS Forum 2007, 14:78-83.
23. Gehrmann J., Matsumo Y., Kreutzberg G. Microglia: intrinsic immunoeffector cell of the brain. Brain Res Rev 1995, 20:269-287.
24. Ghosh S., Wu M.D., Shaftel S.S., Kyrkanides S., LaFerla F.M., Olschowka J.A., O'Banion M.K. Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 2013, 33:5053-5064.
25. Gibson C.J., Hossain M.M., Richardson J.R., Aleksunes L.M. Inflammatory regulation of ATP binding cassette efflux transporter expression and function in microglia. J Pharmacol Exp Ther 2012, 343:650-660.
26. Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R., Samokhvalov I.M., Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
27. Gonzalez-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999, 22:219-240.
28. Graeber M.B. Changing face of microglia. Science 2010, 330:783-788.
29. Gresa-Arribas N., Vieitez C., Dentesano G., Serratosa J., Saura J., Sola C. Modelling neuroinflammation in vitro: a tool to test the potential neuroprotective effect of anti-inflammatory agents. Plos One 2012, 7:9.
30. Gruol D.L., Vo K., Bray J.G. Increased astrocyte expression of IL-6 or CCL2 in transgenic mice alters levels of hippocampal and cerebellar proteins. Front Cell Neurosci 2014, 8:234.
31. Hamelin B.A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998, 19:26-37.
32. Hanisch U.K. Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
33. He G.L., Liu Y., Li M., Chen C.H., Gao P., Yu Z.P., Yang X.S. The amelioration of phagocytic ability in microglial cells by curcumin through the inhibition of EMF-induced pro-inflammatory responses. J Neuroinflamm 2014, 11:49.
34. Hesselgesser J., Ng H.P., Liang M., Zheng W., May K., Bauman J.G., Monahan S., Islam I., Wei G.P., Ghannam A., Taub D.D., Rosser M., Snider R.M., Morrissey M.M., Perez H.D., Horuk R. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 1998, 273:15687-15692.
35. Hickman S.E., El Khoury J. TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 2014, 88:495-498.
36. Ip W.K., Takahashi K., Ezekowitz R.A., Stuart L.M. Mannose-binding lectin and innate immunity. Immunol Rev 2009, 230:9-21.
37. 1. J Thromb Haemost 2011, 10:268-277.
38. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998, 81:582-587.
39. Kettenmann H., Hanischuk Noda M., Verkhratsky A. Physiology of microglia. Physiol Rev 2011, 91:461-553.
40. Kitamura S., Maeda K., Wang Y., Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008, 36:2014-2023.
41. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
42. Kroner A., Greenhalgh A.D., Zarruk J.G., Passos Dos Santos R., Gaestel M., David S. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron 2014, 83:1098-1116.
43. Kurata T., Miyazaki K., Kozuki M., Morimoto N., Ohta Y., Ikeda Y., Abe K. Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. Neurol Res 2012, 34:601-610.
44. Lee J.K., Schuchman E.H., Jin H.K., Bae J.S. Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid β ameliorates Alzheimer's disease in mice by recruiting bone marrow-induced microglia immune responses. Stem cells 2012, 30:1544-1555.
45. Lindberg C., Crisby M., Winblad B., Schultzberg M. Effects of statins on microglia. J Neurosci Res 2005, 82:10-19.
46. Loane D.J., Byrnes K.R. Role of microglia in neurotrauma. Neurother J Am Soc Exp Neurother 2010, 7:366-377.
47. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Progr Neurobiol 2009, 89:277-287.
48. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193:265-275.
49. Lue L.F., Schmitz C., Walker D.G. What happens to microglial TREM2 in Alzheimer's disease: immunoregulatory turned into immunopathogenic?. Neuroscience 2015, 302:138-150.
50. Lund S., Christensen K.V., Hedtjärn M., Mortensen A.L., Hagberg H., Falsig J., Hasseldam H., Schrattenholz A., Pörzgen P., Leis M. The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol 2006, 180:71-87.
51. Luo X.G., Chen S.D. The changing phenotype of microglia from homeostasis to disease. Translat Neurodegener 2012, 1:9.
52. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Progr Neuropsychopharm Biol Psychiatry 2003, 27:741-749.
53. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010, 19:355-361.
54. McGeer P.L., Kawamata T., Walker D.G., Akiyama H., Tooyama I., McGeer E.G. Microglia in degenerative neurological disease. Glia 1993, 7:84-92.
55. McTaggart F., Buckett L., Davidson R., Holdgate G., McCormick A., Schneck D., Smith G., Warwick M. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001, 87(5A):28B-32B.
56. Nakamichi K., Saiki M., Kitani H., Kuboyama Y., Morimoto K., Takayama-Ito M., Kurane I. Suppressive effect of simvastatin on interferon-beta-induced expression of CC chemokine ligand 5 in microglia. Neurosci Lett 2006, 407:205-210.
57. Nakamura Y. Regulating factors for microglial activation. Biol Pharm Bull 2002, 25:945-953.
58. Nakamura Y., Si Q.S., Kataoka K. Lipopolysaccharide-induced microglial activation in culture: temporal profiles of morphological change and release of cytokines and nitric oxide. Neurosci Res 1999, 35:95-100.
59. Napoli I., Neumann H. Protective effects of microglia in multiple sclerosis. Exp Neurol 2010, 225:24-28.
60. Neher J.J., Neniskyte U., Zhao J.W., Bal-Price A., Tolkovsky A.M., Brown G.C. Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death. J Immunol 2011, 186:4973-4983.
61. Nicholls S.J., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R.M., Libby P., Raichlen J.S., Uno K., Borgman M., Wolski K., Nissen S.E. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
62. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., Schoenhagen P., Crowe T., Cain V., Wolski K., Goormastic M., Tuzcu E.M. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565. ASTEROID Investigators.
63. Ohsawa K., Imai Y., Sasaki Y., Kohsaka S. Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem 2004, 88:844-856.
64. Omari K.M., Lutz S.E., Santambrogio L., Lira S.A., Raine C.S. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am J Pathol 2009, 174:164-176.
65. Ozsvári B., Puskás L.G., Nagy L.I., Kanizsai I., Gyuris M., Madácsi R., Fehér L.Z., Gerö D., Szabó C. A cell-microelectronic sensing technique for the screening of cytoprotective compounds. Int J Mol Med 2010, 25:525-530.
66. Prokop S., Miller K.R., Heppner F.L. Microglia actions in Alzheimer's disease. Acta Neuropathol 2013, 126:461-477.
67. Rodriguez G.A., Tai L.M., LaDu M.J., Rebeck G.W. Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. J Neuroinflammation 2014, 11:111.
68. Rottman J.B., Slavin A.J., Silva R., Weiner H.L., Gerard C.G., Hancock W.W. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000, 30:2372-2377.
69. Sasaki Y., Ohsawa K., Kanazawa H., Kohsaka S., Imai Y. Iba1 Is an actin-cross-linking protein in macrophages/microglia. Biochem Biophys Res Commun 2001, 286:292-297.
70. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005, 19:117-125.
71. Schönbeck U., Libby P. Inflammation, immunity, and HMG-CoA reductase Inhibitors: statins as antiinflammatory agents. Circulation 2004, 109(S1):II18-II26.
72. Shimoyama M., De Pons J., Hayman G.T., Laulederkind S.J., Liu W., Nigam R., Petri V., Smith J.R., Tutaj M., Wang S.J., Worthey E., Dwinell M., Jacob H. The Rat Genome Database 2015: genomic, phenotypic and environmental variations and disease. Nucleic Acids Res 2015, 43(Database issue):D743-D750.
73. Shobab L.A., Hsuing G.Y., Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol 2005, 4:841-852.
74. Simon M.S., Rosenberg C.A., Rodabough R.J., Greenland P., Ockene I., Roy H.K., Lane D.S., Cauley J.A., Khandekar J. Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 2012, 22:17-27.
75. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation in hippocampal neurons. Proc Natl Acad Sci USA 1998, 95:6460-6464.
76. Skuljec J., Sun H., Pul R., Bénardais K., Ragancokova D., Moharregh-Khiabani D., Kotsiari A., Trebst C., Stangel M. CCL5 induces a pro-inflammatory profile in microglia in vitro. Cell Immunol 2011, 270:164-171.
77. Streit W.J. Microglia as neuroprotective immunocompetent cells of the CNS. Glia 2002, 40:133-139.
78. Stuart L.M., Takahashi K., Shi L., Savill J., Ezekowitz R.A. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol 2005, 174:3220-3226. Erratum in: J Immunol 175:3447.
79. Szabo M., Gulya K. Development of the microglial phenotype in culture. Neuroscience 2013, 241:280-295.
80. Taylor F., Huffman M.D., Macedo A.F., Moore T.H., Burke M., Davey Smith G., Ward K., Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, 1:CD004816. 2013.
81. van der Most P.J., Dolga A.M., Nijholt I.M., Luiten P.G.M., Eisel U.L. Statins: mechanisms of neuroprotection. Progr Neurobiol 2009, 88:64-75.
82. Veillard N.R., Braunersreuther V., Arnaud C., Burger F., Pelli G., Steffens S., Mach F. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006, 188:51-58.
83. Watanabe K., Jose P.J., Rankin S.M. Eotaxin-2 generation is differentially regulated by lipopolysaccharide and IL-4 in monocytes and macrophages. J Immunol 2002, 168:1911-1918.
84. Weber C., Erl W., Weber K.S., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997, 30:1212-1217.
85. Wierzbicki A.S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Therap 2003, 99:95-112.
86. Worthley D.L., Bardy P.G., Mullighan C.G. Mannose-binding lectin: biology and clinical implications. Intern Med J 2005, 35:548-555.
87. Woudstra C., Lambert D., Anniballi F., De Medici D., Austin J., Fach P. Genetic diversity of the flagellin genes of Clostridium botulinum groups I and II. Appl Environ Microbiol 2013, 79:3926-3932.
88. Wu Y., Wu M., He G., Zhang X., Li W., Gao Y., Li Z., Wang Z., Zhang C. Glyceraldehyde-3-phosphate dehydrogenase: a universal internal control for Western blots in prokaryotic and eukaryotic cells. Anal Biochem 2012, 423:15-22.
89. Yang Y.C., Huang W.F., Chuan L.M., Xiao D.W., Zeng Y.L., Zhou D.A., Xu G.Q., Liu W., Huang B., Hu Q. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells. Chemotherapy 2008, 54:438-446.
90. Zelcer N., Khanlou N., Clare R., Jiang Q., Reed-Geaghan E.G., Landreth G.E., Vinters H.V., Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 2007, 104:10601-10606.
91. Zipp F., Waiczies S., Aktas O., Neuhaus O., Hemmer B., Schraven B., Nitsch R., Hartung H.P. Impact of HMG-CoA reductase inhibition on brain pathology. Trends Pharmacol Sci 2007, 28:342-349.